ArticleFrontiers in endocrinology2024
Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Joint association of body roundness index and HOMA-IR with risk of MASLD in Korean populations.BMC endocrine disorders · 2026Article
- Plasma aldosterone concentration and valvular heart disease in hypertensive patients: a large cross-sectional study.Scientific reports · 2026Article
- Renin-angiotensin-aldosterone system for the management of metabolic dysfunction-associated steatotic liver disease.Hormones (Athens, Greece) · 2026Article
- Multicenter cohort study reveals: composite inflammatory indexs are associated with increased risk of diabetes in patients with hypertension.Frontiers in endocrinology · 2026Article
- Atherogenic index of plasma as a simple marker for NAFLD risk stratification in community-dwelling older adults: a cross-sectional study with incremental predictive value assessment.Frontiers in endocrinology · 2026Article
- Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease.BMC gastroenterology · 2025Article
- Association of hepatic biomarkers with incident diabetes: a mediation analysis of the triglyceride-glucose index in a large Chinese cohort.Lipids in health and disease · 2025Article
- Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.World journal of cardiology · 2025Review
- Association between circadian syndrome and MASLD risk: evidence from a large cross-sectional study.BMC gastroenterology · 2025Article
- Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease.Lipids in health and disease · 2025Article
- Nonlinear association between body roundness index and metabolic dysfunction associated steatotic liver disease in nondiabetic Japanese adults.Scientific reports · 2025Article
- Association of weight-adjusted-waist index with type 2 diabetes mellitus in Chinese urban adults: a cross-sectional study.Frontiers in endocrinology · 2025Article
- Construction and evaluation of a diagnostic model for metabolic dysfunction-associated steatotic liver disease based on advanced glycation end products and their receptors.Frontiers in medicine · 2025Article
- Plasma Aldosterone Elevation in Hypertensive Patients and Association with Urinary Stone Formation: A Large-Scale Population Study from Northwest China.Clinical epidemiology · 2025Article
- Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China.Journal of inflammation research · 2025Article
- Association of plasma aldosterone concentration with peripheral artery disease in hypertensive patients: insights from a large cross-sectional analysis.Frontiers in cardiovascular medicine · 2025Article
- Correlation between hepatic steatosis severity diagnosed by ultrasound and metabolic indexes in elderly patients with MAFLD.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the link between plasma aldosterone concentration (PAC) and the prevalence of metabolic dysfunction-related fatty liver disease (MAFLD) in hypertensive patients. Methods: We analyzed data from 41,131 hospitalized patients from January 1, 2014, to December 31, 2023. Multivariate logistic regression models tested associations, with threshold, subgroup, and sensitivity analyses conducted to validate findings. Results: For each 5-unit increase in PAC, the risk of MAFLD rose by 1.57 times, consistent even in the fully adjusted model. The odds ratios for the Q2, Q3, and Q4 groups compared to Q1 were 1.21, 2.12, and 3.14, respectively. A threshold effect was observed at 14 ng/dL, with subgroup and sensitivity analyses supporting these results. Conclusions: This study reveals a significant positive association between elevated PAC levels and the prevalence of MAFLD in hypertensive patients. These findings underscore the imperative for further large-scale, prospective studies to validate and expand upon this correlation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.